Danyun Ruan on Muck Rack

Danyun Ruan

As seen in: The BMJ, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Danyun

Contact Danyun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer

|
By Yuetong Zhang, Jiaying Chen, Zhaoyuan Fang, Yaxin Zhang, Danyun Ruan, Wenjun Guo, Jianping Liao, Weiping Zhou, Jianpei Lao, Weicheng Fang, Xingyan Pan, Zifeng Wang, Yuanzhong Wu, Rong Deng, Lin Tian, Liqin Wang, Huilin Huang, Jian Zheng, Hezhe Lu, Ruiping Wang, Rona Yaeger, QI Zhao, Wenting Liao, Feng Wang, Yijun Gao, Wenfei Kang
| Cell Press Verified
Keywords KRAS mutant colorectal cancer dual KRAS and EGFR-targeted therapy drug resistance lineage plasticity trans-differentiation Paneth-like cell state Introduction KRAS is one of the most commonly mutated oncogenes in human cancer, with mutations observed in up to 50% of colorectal cancer (CRC) cases.1,2 KRAS-mutant CRC has long posed a therapeutic challenge, with poor prognosis due to limited therapeutic options.3 However, recent breakthroughs with KRAS G12C inhibitors (e.g., sotorasib...
Open in Who Shared Issue with article?

1498 Safety, tolerability and preliminary efficacy of QLP2117, a novel CCR8 antibody, in patients with advanced solid tumors: results from a dose-escalation phase 1a clinical trial | Journal for ImmunoTherapy of Cancer

|
By Hongyun Zhao, Yueyin Pan, Qi Dang, Danyun Ruan
| The BMJ Verified
http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.
Open in Who Shared View Duplicates (151) Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified